NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit ...

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder. Not eligible? Contact the stakeholder organisation that most closely represents your interests and ...

NICE is unable to make a recommendation about the use in the NHS of empagliflozin (Jardiance) for treating type 2 diabetes in people aged 10 to 17 years. This is because Boehringer Ingelheim did not ...

This topic was evaluated as a single technology evaluation by the highly specialised technologies evaluation committee. Because of this, some members of the technology evaluation committees were ...

Tools to help you put the guidance into practice.

NICE is unable to make a recommendation about the use in the NHS of empagliflozin for treating type 2 diabetes in people aged 10 to 17 years. This is because Boehringer Ingelheim has confirmed that it ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

You can now review and comment on this draft guideline which will partially update Advanced breast cancer: diagnosis and treatment (CG81) and Early and locally advanced breast cancer: diagnosis and ...

Suggested remit: To appraise the clinical and cost effectiveness of serplulimab with carboplatin and etoposide within its marketing authorisation for untreated extensive-stage small-cell lung cancer.

10395 - Aprocitentan for treating resistant hypertension TS ID 10395 Technology appraisal guidance Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095 Technology appraisal ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'inputs and eligible population' and 'unit costs' worksheets in the template to reflect ...